

[Saquinavir](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.2. Antiretrovirals](#) [6.4.2.3. Antiretrovirals > Protease inhibitors](#)

Codes ATC: [J05AE01](#)

EMLc

Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Code ICD11: [1C62.Z](#)

INN

Saquinavir

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Solid: 200 mg ; 500 mg

Historique des statuts LME

Ajouté pour la première fois en 2002 ([TRS 914](#))

Modifié en 2007 ([TRS 950](#))

Modifié en 2009 ([TRS 958](#))

Retiré en 2017 ([TRS 1006](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Restriction de poids

> 25 kg

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Saquinavir](#)

DrugBank

[Saquinavir](#)

Résumé des preuves et recommandation du comité d'experts

The Expert Committee recommended the deletion of saquinavir from the Model Lists, noting that that clinical use of the protease inhibitor saquinavir has declined over time with the introduction of newer antiretroviral agents with lower pill burden, similar or greater effectiveness and lower risk of toxicity. Unlike other protease inhibitors, saquinavir is associated with QT prolongation and a requirement for ECG monitoring. Numerous alternative protease inhibitors (with and without ritonavir) remain listed on the EML.